

AL-MUJTAMA AI-RA'IDA MEDICAL COMPANY ANNOUNCES FULL YEAR 2025 RESULTS WITH SUSTAINED REVENUE GROWTH

- Net sales reached SAR 454.7 million in FY 2025, a 5.6% increase year-on-year, reflecting continued expansion of the pharmacy network
- Gross profit of SAR 149.7 million, a 5.4% increase year-on-year, with a gross margin of 32.9%
- Net income after Zakat of SAR 8.4 million, a 5.9% increase year-on-year, demonstrating improving operational profitability
- Earnings per share of SAR 0.88, up from SAR 0.83 in FY 2024
- Strong NUPCO Wasfaty programme revenues of SAR 121.6 million, underpinning recurring government healthcare sales
- Total assets grew to SAR 515.1 million as at 31 December 2025 from SAR 459.5 million as at 31 December 2024

Jeddah, Saudi Arabia, 15 March 2026: Al-Mujtama Al-Ra'ida Medical Company (“Al-Mujtama” or the “Company”, listed on the Saudi Exchange’s Nomu – Parallel Market since November 2023), a leading pharmacy retail chain headquartered in Jeddah, Saudi Arabia, announced its audited financial results for the full year ended 31 December 2025 (FY 2025).

The Company reported net sales of SAR 454.7 million in FY 2025, representing a 5.6% increase compared to FY 2024 (SAR 430.8 million). This performance was underpinned by the continued growth of Al-Mujtama’s retail pharmacy network, strong demand across its pharmaceutical, cosmetics, and medical supplies segments, and significant revenues generated through the NUPCO Wasfaty programme. Net income after Zakat grew 5.9% year-on-year to SAR 8.4 million, while earnings per share improved to SAR 0.88.

Chief Executive Officer, stated:

“FY 2025 has been a year of consistent and disciplined growth for Al-Mujtama. We have continued to expand our pharmacy footprint across Saudi Arabia while delivering improved profitability, reaffirming the strength of our retail pharmacy model. Our participation in the NUPCO Wasfaty programme continues to be a cornerstone of our business, providing a robust and recurring revenue stream that complements our private retail operations. The confidence placed in us by our customers and government partners drives us to maintain the highest standards of pharmaceutical care.

Looking ahead, we remain focused on expanding our branch network, deepening our product and service offering, and capturing the significant growth opportunities presented by Saudi Arabia’s evolving healthcare landscape. With a clear strategy, a dedicated team, and a loyal customer base, Al-Mujtama is well-positioned to deliver sustained value for our shareholders and communities.”

FINANCIAL REVIEW

Net Sales of SAR 454.7 million in FY 2025 (FY 2024: SAR 430.8 million) represented a 5.6% increase year-on-year (YoY). Growth was driven by the continued expansion of the Company's retail pharmacy network and robust demand across pharmaceutical, cosmetics, and medical device categories. The NUPCO Wasfaty programme contributed SAR 121.6 million to FY 2025 net sales, further demonstrating Al-Mujtama's strong position in government-linked healthcare distribution.

Gross Profit of SAR 149.7 million in FY 2025 (FY 2024: SAR 142.1 million) represented a 5.4% increase YoY. Gross margin remained stable at 32.9% (FY 2024: 33.0%), reflecting disciplined cost management and a healthy product mix across the Company's diverse pharmacy operations.

Net Operating Income improved significantly to SAR 10.7 million in FY 2025 (FY 2024: SAR 7.7 million), a 38.6% increase YoY, reflecting the Company's continued focus on operational efficiency even as it invests in its network expansion.

Net Income After Zakat grew 5.9% to SAR 8.4 million in FY 2025 (FY 2024: SAR 7.9 million). Finance costs of SAR 9.25 million (FY 2024: SAR 7.97 million).

Operating Cash Flow of SAR 25.0 million in FY 2025 (FY 2024: SAR 43.7 million). The decrease reflects a planned increase in inventory to SAR 192.9 million (FY 2024: SAR 144.4 million), driven by the Company's deliberate stock build ahead of further branch openings and network expansion.

Cash and Cash Equivalents increased to SAR 6.9 million at year-end (FY 2024: SAR 2.2 million), with total assets reaching SAR 515.1 million (FY 2024: SAR 459.5 million), reflecting the Company's strengthened balance sheet and expanded operational footprint.

STRATEGY AND OUTLOOK

Al-Mujtama's strategy for 2026 and beyond is anchored on three pillars: continued expansion of its pharmacy branch network across Saudi Arabia, deepening penetration of government healthcare programmes such as NUPCO Wasfaty, and enhancing the quality and breadth of its product offering to customers.

Alongside network expansion, Al-Mujtama is undertaking several operational and commercial initiatives aimed at strengthening its competitive position and improving financial performance. These initiatives include the implementation of a new CRM platform to enhance personalized customer engagement and loyalty programme effectiveness, expansion of online sales channels through both the Company's in-house platform and third-party aggregators, and improvements in category management to optimize product assortment and merchandising across stores.

Operational efficiency remains a key focus area. The Company is implementing warehouse automation and advanced inventory management systems to streamline distribution processes, improve stock availability, and reduce operating costs. Additionally, initiatives such as automated replenishment models and the expansion of consignment-based supplier partnerships are expected to enhance working capital efficiency and inventory turnover.

Al-Mujtama is also expanding its healthcare service offerings through the planned introduction of in-pharmacy clinics and partnerships with healthcare providers. These initiatives aim to increase customer footfall, broaden the Company's healthcare ecosystem, and create additional revenue streams beyond traditional pharmacy retail.

Saudi Arabia's healthcare sector continues to benefit from strong structural tailwinds, including a growing and ageing population, rising awareness of preventative health, and the Kingdom's significant investment in health infrastructure as part of Vision 2030. These dynamics create compelling opportunities for Al-Mujtama to further scale its operations and strengthen its position as a leading retail pharmacy group in the Kingdom.

Guided by a clear strategic vision and a commitment to operational excellence, Al-Mujtama is confident in its ability to deliver sustainable growth and long-term value for its shareholders.

Summary Financials (for the full year ended 31 December 2025)

BALANCE SHEET (SAR)	31 Dec 2025	31 Dec 2024
Current Assets	241,577,460	188,131,893
Non-Current Assets	273,493,708	271,332,967
Total Assets	515,071,168	459,464,860
Current Liabilities	226,680,727	175,121,810
Non-Current Liabilities	142,072,948	146,202,417
Total Liabilities	368,753,675	321,324,227
Total Equity	146,317,493	138,140,633
Total Liabilities and Shareholders' Equity	515,071,168	459,464,860

INCOME STATEMENT (SAR)	FY 2025	FY 2024
Net Sales	454,725,771	430,750,292
Cost of Sales	(304,978,173)	(288,627,224)
Gross Profit	149,747,598	142,123,068
Selling & Distribution Expenses	(124,434,887)	(120,497,747)
General & Administrative Expenses	(14,593,198)	(13,889,043)
Net Operating Income	10,719,513	7,736,278
Finance Costs	(9,247,932)	(7,970,726)
Share of Losses from JVs	(75,000)	—
Other Income	7,392,411	8,521,048
Income Before Zakat	8,788,992	8,286,600
Zakat Charge	(397,343)	(359,381)
Net Income After Zakat	8,391,649	7,927,219
Earnings Per Share (Basic & Diluted) (SAR)	0.88	0.83

CASH FLOW STATEMENT (SAR)	FY 2025	FY 2024
Net Cash from Operating Activities	24,991,456	43,663,659
Net Cash used in Investing Activities	(23,096,273)	(28,019,597)
Net Cash from / (used in) Financing Activities	2,827,202	(26,464,570)
Net Change in Cash & Cash Equivalents	4,722,385	(10,820,508)
Cash & Cash Equivalents — Beginning of Year	2,179,548	13,000,056
Cash & Cash Equivalents — End of Year	6,901,933	2,179,548

— Ends —

ABOUT AL-MUJTAMA AL-RA'IDA MEDICAL COMPANY

Al-Mujtama Al-Ra'ida Medical Company (Arabic: شركة المجتمع الراحدة الطبية) is a Saudi Joint Stock Company incorporated in the Kingdom of Saudi Arabia and listed on the Saudi Exchange's Nomu – Parallel Market since November 2023. The Company is headquartered in the Al-Hamdiyah district of Jeddah and operates a growing chain of retail pharmacies across Saudi Arabia, selling pharmaceuticals, cosmetics, medical devices, and baby care products.

Founded in 2013, Al-Mujtama has built a well-established presence in the Kingdom's retail pharmacy sector, operating under multiple commercial registrations and branch locations across the country. The Company is an active participant in the NUPCO Wasfaty programme, delivering pharmacy services to government-sponsored beneficiaries, reinforcing its dual exposure to both private retail and public healthcare channels.

The Company has a share capital of SAR 95 million, comprising 9.5 million shares at a par value of SAR 10 per share.

Al-Mujtama's financial statements are audited by Talal Abu-Ghazaleh & Co., a professional services firm.

For more information, please visit us on: <https://www.almujtama.com.sa/>